Travere Therapeutics Inc (TVTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $4.86B
Last updated: Nov 17, 2026 at 11:06 AM ET
Travere Therapeutics Inc (TVTX) Financials: Revenue, Profit and Cash Flow
Travere Therapeutics reported revenue of $490.73M for the fiscal year ended Dec 31, 2025, up 110.5% from the year before. That year, net income was -$25.55M with a net margin of -5.2%, operating cash flow was $37.78M and free cash flow was -$20.37M. The quarter ended Sep 30, 2026 had revenue of $224.56M and net income of -$52.34M.
Revenue and Margins
The operating margin was -12.8% in the fiscal year ended Dec 2025, the highest of the 6 years shown with an operating margin. Over the 9 years to Dec 2025, revenue grew from $133.59M, a compound annual rate of 15.6%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $490.73M | +110.5% | 97.9% | -12.8% | -5.2% |
| Dec 2024 | $233.18M | +60.5% | 96.7% | -138.9% | -137.9% |
| Dec 2023 | $145.24M | +32.7% | 92.1% | -267.2% | -76.7% |
| Dec 2022 | $109.46M | -17.0% | 96.0% | -292.2% | -254.4% |
| Dec 2021 | $131.84M | -33.5% | 97.1% | -151.3% | -136.6% |
| Dec 2020 | $198.32M | +13.1% | 96.9% | -88.8% | -85.4% |
| Dec 2019 | $175.34M | +6.8% | 97.0% | -56.9% | -83.5% |
| Dec 2018 | $164.25M | +6.0% | 96.6% | -48.7% | -62.5% |
| Dec 2017 | $154.94M | +16.0% | 97.7% | -34.7% | -38.6% |
| Dec 2016 | $133.59M | N/A | 96.6% | -43.6% | -35.9% |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $490.73M | $233.18M | $145.24M | $109.46M | $131.84M | $198.32M | $175.34M | $164.25M | $154.94M | $133.59M |
| Cost of revenue | $10.34M | $7.74M | $11.45M | $4.42M | $3.82M | $6.13M | $5.23M | $5.53M | $3.60M | $4.55M |
| Gross profit | $480.39M | $225.43M | $133.79M | $105.04M | $128.02M | $192.19M | $170.10M | $158.72M | $151.33M | $129.04M |
| Research and development | $206.01M | $282.70M | $244.99M | $227.33M | $201.16M | $131.77M | $140.96M | $123.76M | $78.17M | $70.85M |
| Operating income | -$62.82M | -$323.83M | -$388.14M | -$319.81M | -$199.43M | -$176.16M | -$99.81M | -$80.04M | -$53.79M | -$58.21M |
| Net income | -$25.55M | -$321.55M | -$111.40M | -$278.48M | -$180.09M | -$169.43M | -$146.43M | -$102.68M | -$59.73M | -$47.90M |
| EBITDA | $22.22M | -$265.77M | -$326.25M | -$299.42M | -$184.46M | -$145.16M | N/A | -$73.39M | -$38.67M | -$38.79M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $224.56M | $169.58M | $127.20M | $129.69M | $164.86M | $114.45M | $81.73M | $74.79M | $62.90M | $54.12M | $41.37M | $45.06M |
| Gross profit | $221.70M | $167.41M | $100.43M | $127.14M | $163.27M | $112.93M | $77.05M | $72.23M | $61.27M | $41.71M | $39.87M | $28.64M |
| Operating income | -$68.11M | $3.95M | -$36.91M | -$32.43M | $24.93M | -$12.65M | -$42.67M | -$60.74M | -$56.15M | -$67.05M | -$139.24M | -$82.84M |
| Net income | -$52.34M | -$34.80M | -$37.10M | $2.73M | $25.71M | -$12.76M | -$41.23M | -$60.26M | -$54.81M | -$70.41M | -$136.06M | -$90.17M |
Balance Sheet
As of Dec 2025, total debt of $317.60M exceeded cash and equivalents by $224.56M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $605.19M | $594.13M | $788.91M | $672.59M | $776.63M | $607.44M | $604.80M | $709.16M | $520.35M | $525.28M |
| Current assets | $437.56M | $416.70M | $616.77M | $486.44M | $582.83M | $410.41M | $429.06M | $495.68M | $325.81M | $332.35M |
| Cash and equivalents | $93.03M | $58.53M | $58.18M | $61.69M | $165.75M | $84.77M | $62.44M | $102.87M | $99.39M | $41.00M |
| Total liabilities | $490.36M | $535.05M | $588.10M | $629.73M | $474.52M | $396.23M | $383.60M | $390.91M | $227.21M | $217.51M |
| Short-term debt | $5.88M | $74.08M | $4.91M | $4.43M | $3.91M | $357.00K | $2.61M | $22.46M | N/A | N/A |
| Long-term debt | $311.72M | $310.31M | $377.26M | $375.55M | $226.58M | $215.34M | $204.86M | $195.09M | $45.08M | N/A |
| Shareholder equity | $114.83M | $59.08M | $200.81M | $42.85M | $302.11M | $211.21M | $221.20M | $318.25M | $293.13M | $307.77M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $848.23M | $799.36M | $555.19M | $605.19M | $538.58M | $555.31M | $548.80M | $594.13M | $504.41M | $551.12M | $663.55M | $788.91M |
| Total liabilities | $825.64M | $774.84M | $456.46M | $490.36M | $465.02M | $522.56M | $515.98M | $535.05M | $534.86M | $535.97M | $589.48M | $588.10M |
| Cash and equivalents | $123.54M | $117.73M | $78.36M | $93.03M | $110.93M | $75.15M | $61.90M | $58.53M | $36.41M | $32.29M | $43.25M | $58.18M |
| Shareholder equity | $22.58M | $24.52M | $98.73M | $114.83M | $73.56M | $32.75M | $32.82M | $59.08M | -$30.45M | $15.15M | $74.07M | $200.81M |
Cash Flow
In the fiscal year ended Dec 2025, capital expenditures exceeded operating cash flow, leaving negative free cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $37.78M | -$237.47M | -$280.02M | -$186.29M | -$14.79M | -$42.74M | -$58.21M | -$24.96M | $7.40M | -$1.60M |
| Capital expenditures | $58.16M | $101.21M | $41.59M | $28.37M | $24.15M | $119.84M | $15.56M | $19.70M | $14.01M | $11.92M |
| Free cash flow | -$20.37M | -$338.69M | -$321.61M | -$214.66M | -$38.94M | -$162.59M | -$73.78M | -$44.66M | -$6.61M | -$13.52M |
| Investing cash flow | $27.89M | $99.33M | $55.78M | -$32.55M | -$137.62M | -$61.33M | $19.86M | -$203.29M | $45.60M | $10.37M |
| Financing cash flow | -$33.47M | $139.42M | $218.75M | $117.57M | $231.68M | $127.71M | -$2.08M | $231.86M | $5.45M | -$5.69M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $98.20M | $58.07M | -$40.37M | $60.68M | $14.32M | $4.98M | -$42.19M | -$35.72M | -$42.51M | -$40.24M | -$119.00M | -$70.47M |
| Capital expenditures | $22.18M | $22.18M | $22.18M | $18.86M | $140.00K | $235.00K | $11.78M | $9.56M | $8.19M | $11.99M | $6.47M | $5.53M |
| Free cash flow | $76.03M | $35.89M | -$62.54M | $41.81M | $14.18M | $4.75M | -$53.98M | -$45.28M | -$50.70M | -$52.24M | -$125.47M | -$76.00M |
Frequently Asked Questions About TVTX
What is Travere Therapeutics' annual revenue?
Travere Therapeutics reported revenue of $490.73M for the fiscal year ended Dec 31, 2025.
How fast is Travere Therapeutics' revenue growing?
Revenue was up 110.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 64.9%.
Is Travere Therapeutics profitable?
No. Travere Therapeutics reported net income of -$25.55M for the fiscal year ended Dec 31, 2025, with a net margin of -5.2%.
How much free cash flow does TVTX generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $37.78M minus capital expenditures of $58.16M produced free cash flow of -$20.37M.
How much debt does Travere Therapeutics have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $311.72M, short-term debt of $5.88M and cash and equivalents of $93.03M.
TVTX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts